1. Metronomic Capecitabine as Maintenance Treatment after First-Line Induction with XELOX for Metastatic Colorectal Cancer Patients
- Source: Medicine (Baltimore), 2020
- Summary: Metronomic capecitabine maintenance therapy significantly improved progression-free survival (PFS) compared to observation alone in metastatic colorectal cancer (mCRC) patients, though overall survival (OS) was not significantly different. This indicates a potential benefit of metronomic chemotherapy for disease control.
2. MOMENTUM: A Phase I Trial Investigating Two Schedules of Capecitabine with Aflibercept in Patients with Gastrointestinal and Breast Cancer
- Source: Clinical Colorectal Cancer, 2020
- Summary: This study showed that metronomic capecitabine with aflibercept was feasible and had a manageable safety profile with some anti-tumor activity in chemorefractory gastrointestinal and breast cancer patients.
3. Metronomic Capecitabine with Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei
- Source: Clinical Colorectal Cancer, 2019
- Summary: The combination of metronomic capecitabine and cyclophosphamide demonstrated a disease control rate (DCR) of 87% and a manageable safety profile, indicating potential survival benefits for patients with pseudomyxoma peritonei.
4. Phase II Randomized Study of Maintenance Treatment with Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy after First-Line Induction with FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients: The MOMA Trial
- Source: European Journal of Cancer, 2019
- Summary: This study found that adding metronomic chemotherapy to bevacizumab maintenance therapy did not significantly improve PFS compared to bevacizumab alone. However, the treatment was well tolerated.
5. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial
- Source: JAMA Oncology, 2017
- Summary: Combining low-dose cyclophosphamide with an MVA-5T4 vaccine significantly improved PFS and OS in metastatic colorectal cancer patients, highlighting the potential for enhanced antitumor immunity and survival benefits.
6. Continuous, Low-Dose Capecitabine for Patients with Recurrent Colorectal Cancer
- Source: Medical Oncology, 2015
- Summary: Low-dose metronomic capecitabine was moderately active and well-tolerated in pretreated or frail patients with recurrent colorectal cancer, showing potential benefits for disease control and survival.
7. A Phase 1 Trial of Imatinib, Bevacizumab, and Metronomic Cyclophosphamide in Advanced Colorectal Cancer
- Source: British Journal of Cancer, 2013
- Summary: The combination of imatinib, bevacizumab, and metronomic cyclophosphamide was safe and tolerable, with a subset of patients experiencing prolonged stable disease, suggesting potential benefits for survival.
8. A Randomized Study of KRAS-Guided Maintenance Therapy with Bevacizumab, Erlotinib, or Metronomic Capecitabine after First-Line Induction Treatment of Metastatic Colorectal Cancer: The Nordic ACT2 Trial
- Source: Annals of Oncology, 2016
- Summary: The trial indicated that low-dose capecitabine as maintenance therapy did not significantly improve PFS or OS compared to other maintenance strategies but showed enough potential to warrant further investigation.
9. Dosage Escalation Study of S-1 and Irinotecan in Metronomic Chemotherapy Against Advanced Colorectal Cancer
- Source: Kurume Medical Journal, 2009
- Summary: This phase I study established the recommended dose for a metronomic chemotherapy regimen with S-1 and irinotecan, demonstrating acceptable safety and promising efficacy for further clinical trials.
Overall, these studies suggest that low-dose or metronomic chemotherapy can positively impact disease control and progression-free survival in various cancers, particularly colorectal cancer. While overall survival improvements are not always statistically significant, the approach is generally well-tolerated and offers promising benefits for disease management and progression-free survival.